The trajectory of companies tied to flagship drugs like Viagra presents a nuanced investment picture. While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the patent expiration in key regions has introduced considerable volatility. Investors are now facing the effect of rival medications